Abstract
CXCR3 was cloned and identified as a receptor for CXCL9 and CXCL10 by Loetscher, et al., in 1996 [1], and was subsequently identified as a receptor for CXCL11 [2]. CXCL9, CXCL10 and CXCL11 are selective, potent agonists of CXCR3 (Kd 0.1–5 nM) [1]–[4]. Additional chemokines have been reported to bind to CXCR3 (e.g., CXCL13 [5] and CCL11 [6]), however the reported affinities are generally weak and the biological significance of the interactions is questionable. Similarly, the ligands for CXCR3 have been reported to be antagonists of CCR3 [7] and CCR5 [8], but high concentrations of the CXCR3 ligands are required to achieve inhibition of CCR3 or CCR5 biological functions.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B (1996) Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184: 799–802
Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE et al (1998) Interferon-inducible T cell alpha chemoattractant (ITAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 187: 2009–2021
Weng Y, Siciliano SJ, Waldburger KE, Sirotina-Meisher A, Staruch MJ, Daugherty BL, Gould SL, Springer MS, DeMartino JA (1998) Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem 273: 18288–18291
Loetscher M, Loetscher P, Brass N, Meese E, Moser B (1998) Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 28: 3696–3705
Jenh CH, Cox MA, Hipkin W, Lu T, Pugliese-Sivo C, Gonsiorek W, Chou CC, Narula SK, Zavodny PJ (2001) Human B cell-attracting chemokine 1 (BCA-1; CXCL13) is an agonist for the human CXCR3 receptor. Cytokine 15: 113–121
Xanthou G, Duchesnes CE, Williams TJ, Pease JE (2003) CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. Eur J Immunol 33: 2241–2250
Loetscher P, Pellegrino A, Gong JH, Mattioli I, Loetscher M, Bardi G, Baggiolini M, Clark-Lewis I (2001) The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 276: 2986–2991
Petkovic V, Moghini C, Paoletti S, Uguccioni M, Gerber B (2004) I-TAC/CXCL11 is a natural antagonist for CCR5. J Leukoc Biol 76: 701–708
Agostini C, Calabrese F, Rea F, Facco M, Tosoni A, Loy M, Binotto G, Valente M, Trentin L, Semenzato G (2001) Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 158: 1703–1711
Melter M, Exeni A, Reinders ME, Fang JC, McMahon G, Ganz P, Hancock WW, Briscoe DM (2001) Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 104: 2558–2564
Goddard S, Williams A, Morland C, Qin S, Gladue R, Hubscher SG, Adams DH (2001) Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants. Transplantation 72: 1957–1967
Zhao DX, Hu Y, Miller GG, Luster AD, Mitchell RN, Libby P (2002) Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J Immunol 169: 1556–1560
Fahmy NM, Yamani MH, Starling RC, Ratliff NB, Young JB, McCarthy PM, Feng J, Novick AC, Fairchild RL (2003) Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation 75: 72–78
Kao J, Kobashigawa J, Fishbein MC, MacLellan WR, Burdick MD, Belperio JA, Strieter RM (2003) Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease. Circulation 107: 1958–1961
Fahmy NM, Yamani MH, Starling RC, Ratliff NB, Young JB, McCarthy PM, Feng J, Novick AC, Fairchild RL (2003) Chemokine and receptor-gene expression during early and late acute rejection episodes in human cardiac allografts. Transplantation 75: 2044–2047
Hu H, Aizenstein BD, Puchalski A, Burmania JA, Hamawy MM, Knechtle SJ (2004) Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant 4: 432–437
Panzer U, Reinking RR, Steinmetz OM, Zahner G, Sudbeck U, Fehr S, Pfalzer B, Schneider A, Thaiss F, Mack M et al (2004) CXCR3 and CCR5 positive T-cell recruitment in acute human renal allograft rejection. Transplantation 78: 1341–1350
Hancock WW, Lu B, Gao W, Csizmadia V, Faia K, King JA, Smiley ST, Ling M, Gerard NP, Gerard C (2000) Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 192: 1515–1520
Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD (2001) Donorderived IP-10 initiates development of acute allograft rejection. J Exp Med 193: 975–980
Miura M, Morita K, Kobayashi H, Hamilton TA, Burdick MD, Strieter RM, Fairchild RL (2001) Monokine induced by IFN-gamma is a dominant factor directing T cells into murine cardiac allografts during acute rejection. J Immunol 167: 3494–3504
Belperio JA, Keane MP, Burdick MD, Lynch JP 3rd, Xue YY, Li K, Ross DJ, Strieter RM (2002) Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol 169: 1037–1049
Baker MS, Chen X, Rotramel AR, Nelson JJ, Lu B, Gerard C, Kanwar Y, Kaufman DB (2003) Genetic deletion of chemokine receptor CXCR3 or antibody blockade of its ligand IP-10 modulates posttransplantation graft-site lymphocytic infiltrates and prolongs functional graft survival in pancreatic islet allograft recipients. Surgery 134: 126–133
Duffner U, Lu B, Hildebrandt GC, Teshima T, Williams DL, Reddy P, Ordemann R, Clouthier SG, Lowler K, Liu C et al (2003) Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol 31: 897–902
Belperio JA, Keane MP, Burdick MD, Lynch JP 3rds, Zisman DA, Xue YY, Li K, Ardehali A, Ross DJ, Strieter RM (2003) Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection. J Immunol 171: 4844–4852
Zhang Z, Kaptanoglu L, Tang Y, Ivancic D, Rao SM, Luster A, Barrett TA, Fryer J (2004) IP-10-induced recruitment of CXCR3 host T cells is required for small bowel allograft rejection. Gastroenterology 126: 809–818
Hildebrandt GC, Corrion LA, Olkiewicz KM, Lu B, Lowler K, Duffner UA, Moore BB, Kuziel WA, Liu C, Cooke KR (2004) Blockade of CXCR3 receptor: ligand interactions reduces leukocyte recruitment to the lung and the severity of experimental idiopathic pneumonia syndrome. J Immunol 173: 2050–2059
Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM et al (1999) Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 103: 807–815
Balashov KE, Rottman JB, Weiner HL, Hancock WW (1999) CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci 96: 6873–6878
Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN (2000) Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol 26: 133–142
Mahad DJ, Howell SJ, Woodroofe MN (2002) Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 72: 498–502
Sorensen TL, Trebst C, Kivisakk P, Klaege KL, Majmudar A, Ravid R, Lassmann H, Olsen DB, Strieter RM, Ransohoff RM et al (2002) Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J Neuroimmunol 127: 59–68
Klein RS, Izikson L, Means T, Gibson HD, Lin E, Sobel RA, Weiner HL, Luster AD (2004) IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis. J Immunol 172: 550–559
Narumi S, Kaburaki T, Yoneyama H, Iwamura H, Kobayashi Y, Matsushima K (2002) Neutralization of IFN-inducible protein 10/CXCL10 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol 32: 1784–1791
Fife BT, Kennedy KJ, Paniagua MC, Lukacs NW, Kunkel SL, Luster AD, Karpus WJ (2001) CXCL10 (IFN-γ-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 166: 7617–7624
Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD (2002) IFN-g-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168: 3195–3204
Liu MT, Chen BP, Oertel P, Buchmeier MJ, Armstrong D, Hamilton TA, Lane TE (2000) The T cell chemoattractant IFN-inducible protein 10 is essential in host defense against viral-induced neurologic disease. J Immunol 165: 2327–2330
Panitch HS, Hirsch RL, Haley AS, Johnson KP (1987) Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1(8538): 893–895
Skurkovich S, Boiko A, Beliaeva I, Buglak A, Alekseeva T, Smirnova N, Kulakova O, Tchechonin V, Gurova O, Deomina T et al (2001) Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. Multiple Sclerosis 7: 277–284
Axte JM, Foley JJ, Kingsbury WD, Sarau HM (2003) International publication WO 03/101970
Watson RJ, Meissner JWG, Owen DA (2004) International publication WO 04/94381
Gao P, Zhou XY, Yashiro-Ohtani Y, Yang YF, Sugimoto N, Ono S, Nakanishi T, Obikata S, Imanishi T, Egawa T et al (2003) The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two TH1 chemokine receptors CCR5 and CXCR3. J Leukocyte Biol 73: 273–280
Schall TJ, Dairaghi DJ, McMaster B (2001) International publication WO 01/16114
Medina JC, Johnson MG, Li AR, Jiwen L, Huang AX, Zhu L, Marcus AP (2002) International publication WO 02/083143
Berry K, Friedrich M, Kersey K, Stempien MJ, Wagner F, van Lier JJ, Sabat R, Wolk K (2004) Evaluation of T0906487, a CXCR3 antagonist, in a Phase 2a Psoriasis Trial. Inflammation Research Association Biannual meeting, Lake George, NY, September, 2004. Inflammation Research 53: S222
Collins TL, Johnson M, Li A.-R, Liu J, Huang A, Zhu L, Marcus A, Danao J, Sablan E, Kumer J et al (2003) T487: A selective and potent small molecule antagonist of CXCR3. 6th World Congress on Inflammation, Vancouver, British Columbia, Canada; August 02–06 2003. Inflammation Research 52(Suppl 2): 118
Floren LC, Berry K, Tonn G, Ye Q, Wright M, Huang AX, Wang X, Marcus A, Johnson M, Collins T et al (2003) T0906487 (T487), a novel CXCR3 antagonist: First time in human study of safety and pharmacokinetics. 6th World Congress on Inflammation, Vancouver, British Columbia, Canada; August 02–06 2003. Inflammation Research 52(Suppl 2): 159
Owen DA, Watson RJ, Meissner JWG, Allen DR (2005) International publication WO 05/003127
Watson RJ, Meissner JWG, Christie MI, Owen DA (2003) International publication WO 03/070242
Ohshima E, Sone H, Kotera O, Komatsu R, Larosa GJ, Luly JR (2002) International publication WO 02/085862
Lin C-C, Liu J-F, Chang L-W, Chen S-J, Xiang Y, Cheng P, Jang J-J (2004) US Patent application publication US 2004/0209902
Salomon I, Netzer N, Wildbaum G, Schif-Zuck S, Maor G, Karin N (2002) Targeting the function of IFN-γ-inducible protein 10 suppresses ongoing adjuvant arthritis. J Immunol 169: 2685–2693
Singh UP, Singh S, Taub DD, Lillard JW Jr. (2003) Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10-/- mice. J Immunol 171: 1401–1406
Howard M, Deshpande S, Ferlin W, Arimilli S. US patent 6,171, 590
Arimilli S, Ferlin W, Deshpande S, Mocci S (2002) US patent application publication 2002/0039578
Balasa B, Tsurushita N, Landolfi N (2004) International publication WO 04/101511
Clark-Lewis I, Mattioli I, Gong J-H, Loetscher P (2003) Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 278: 289–295
Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G, Detheux M, Parmentier M, Durinx C, Lambeir A-M et al (2001) Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 98: 3554–3561
Van Damme J, Proost P (2002) International publication WO 02/059301
Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, Borlat F, Wells TNC, Kosco-Vilbois MH (2003) Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci 100: 1885–1890
Lau EK, Paavola CD, Johnson Z, Gaudry J-P, Geretti E, Borlat F, Kungl AJ, Proudfoot AE, Handel TM (2004) Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1. J Biol Chem 279: 22294–22305
Proudfoot A, Kosco-Vilbois M (2003) International publication WO 03/106488
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Birkhäuser Verlag Basel/Switzerland
About this chapter
Cite this chapter
Collins, T.L., Johnson, M.G., Medina, J.C. (2007). Antagonists of CXCR3: a review of current progress. In: Neote, K., Letts, G.L., Moser, B. (eds) Chemokine Biology — Basic Research and Clinical Application. Progress in Inflammation Research. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-7437-2_6
Download citation
DOI: https://doi.org/10.1007/978-3-7643-7437-2_6
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-7195-1
Online ISBN: 978-3-7643-7437-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)